An analyst downgraded the healthcare stock.
Compare GKOS Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Glaukos
Proposed rates from CMS for fiscal 2022 weren't what investors expected.
Investors would be wise to steer clear of the bigger, more mainstream names until the recent volatility has run its course
Acquisition news was the culprit behind the hit to shares of the ophthalmic medical technology and pharmaceutical company.
Glaukos makes a bid for Avedro in an all-stock transaction.
Shares of this mid-cap ophthalmic medical tech and pharmaceutical company have soared 111% over the last year.
Find out how favorable economic data once again lifted the market.
Glaukos stock gets a boost from a competitor's failure.
Shares tumble after a Wall Street analyst cuts his rating. Here's what investors need to know.
Find out why these stocks dropped on a positive day for the market.